GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Avrobio Inc (NAS:AVRO) » Definitions » PB Ratio

Avrobio (Avrobio) PB Ratio : 0.57 (As of Apr. 26, 2024)


View and export this data going back to 2018. Start your Free Trial

What is Avrobio PB Ratio?

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2024-04-26), Avrobio's share price is $1.21. Avrobio's Book Value per Share for the quarter that ended in Dec. 2023 was $2.12. Hence, Avrobio's PB Ratio of today is 0.57.

The historical rank and industry rank for Avrobio's PB Ratio or its related term are showing as below:

AVRO' s PB Ratio Range Over the Past 10 Years
Min: 0   Med: 0   Max: 1.92
Current: 0.57

During the past 8 years, Avrobio's highest PB Ratio was 1.92. The lowest was 0.00. And the median was 0.00.

AVRO's PB Ratio is ranked better than
90.31% of 1310 companies
in the Biotechnology industry
Industry Median: 2.385 vs AVRO: 0.57

During the past 12 months, Avrobio's average Book Value Per Share Growth Rate was 23.70% per year. During the past 3 years, the average Book Value Per Share Growth Rate was -29.70% per year. During the past 5 years, the average Book Value Per Share Growth Rate was -21.70% per year.

During the past 8 years, the highest 3-Year average Book Value Per Share Growth Rate of Avrobio was -8.90% per year. The lowest was -33.70% per year. And the median was -29.70% per year.

Back to Basics: PB Ratio


Avrobio PB Ratio Historical Data

The historical data trend for Avrobio's PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Avrobio PB Ratio Chart

Avrobio Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
PB Ratio
Get a 7-Day Free Trial 3.42 2.28 0.99 0.42 0.64

Avrobio Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.42 0.83 0.34 0.67 0.64

Competitive Comparison of Avrobio's PB Ratio

For the Biotechnology subindustry, Avrobio's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Avrobio's PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Avrobio's PB Ratio distribution charts can be found below:

* The bar in red indicates where Avrobio's PB Ratio falls into.



Avrobio PB Ratio Calculation

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.

Avrobio's PB Ratio for today is calculated as follows:

PB Ratio=Share Price/Book Value per Share (Q: Dec. 2023)
=1.21/2.122
=0.57

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.


Avrobio  (NAS:AVRO) PB Ratio Explanation

Unlike valuation ratios relative to the earning power such as PE Ratio, PE Ratio without NRI, PS Ratio, Price-to-Operating-Cash-Flow , or Price-to-Free-Cash-Flow, the PB Ratio measures the valuation of the stock relative to the underlying asset of the company.

The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.


Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.


Avrobio PB Ratio Related Terms

Thank you for viewing the detailed overview of Avrobio's PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Avrobio (Avrobio) Business Description

Traded in Other Exchanges
N/A
Address
100 Technology Square, Sixth Floor, Cambridge, MA, USA, 02139
Avrobio Inc is a clinical-stage gene therapy company. It is engaged in developing potentially curative ex vivo lentiviral gene therapies to treat rare diseases following a single dose treatment regimen. The company's pipeline includes AVR-RD-04 for the treatment of cystinosis; AVR-RD-02 for the treatment of Gaucher disease type 1; AVR-RD-05 for the treatment of Hunter syndrome; AVR-RD-06 for the treatment of Gaucher disease type 3; and AVR-RD-03 for the treatment of Pompe disease.
Executives
Azadeh Golipour officer: Chief Technology Officer ONE KENDALL SQUARE, BLD. 300 - SUITE 201, CAMBRIDGE MA 02139
Essra Ridha officer: Chief Medical Officer C/O AVROBIO, INC., ONE KENDALL SQUARE, BLDG 300 - SUITE 201, CAMBRIDGE MA 02139
Philip J. Vickers director C/O REVANCE THERAPEUTICS, INC., 7555 GATEWAY BOULEVARD, NEWARK CA 94560
Christopher Mason officer: Chief Scientific Officer C/O KRYSTAL BIOTECH, INC., 2100 WHARTON STREET, SUITE 701, PITTSBURGH PA 15203
Phillip B. Donenberg director C/O AVEXIS, INC., 2275 HALF DAY ROAD, SUITE 200, BANNOCKBURN IL 60015
Diana Escolar officer: Chief Medical Officer C/O MIRAGEN THERAPEUTICS, INC., 6200 LOOKOUT ROAD, BOULDER CO 80301
Gail M Farfel director 142 TEMPLE STREET, SUITE 205, NEW HAVEN CT 06510
Deanna M Petersen officer: Chief Business Officer 45 FIRST AVENUE, WALTHAM MA 02451
Geoffrey Mackay director, officer: See Remarks C/O AVROBIO, INC., ONE KENDALL SQ, BLDG. 300, STE. 201, CAMBRIDGE MA 02139
Christopher Paige director C/O AVROBIO INC, ONE KENDALL SQ, BLDG 300, STE 201, CAMBRIDGE MA 02139
Atlas Venture Fund X, L.p. 10 percent owner 400 TECHNOLOGY SQUARE, 10TH FLOOR, CAMBRIDGE MA 02139
Atlas Venture Associates Opportunity I, Llc other: See Remarks 400 TECHNOLOGY SQUARE, 10TH FLOOR, CAMBRIDGE MA 02139
Atlas Venture Associates Opportunity I, L.p. other: See Remarks 400 TECHNOLOGY SQUARE, 10TH FLOOR, CAMBRIDGE MA 02139
Atlas Venture Opportunity Fund I, L.p. other: See Remarks 400 TECHNOLOGY SQUARE, 10TH FLOOR, CAMBRIDGE MA 02139
Bruce Booth director 890 WINTER STREET, SUITE 320, WALTHAM MA 02451